Finance

Lists
Q3 2026 earnings • released • EPS beat +17.23% • Revenue beat +8.09%
See results
INDV:NASDAQ
Indivior Pharmaceuticals Inc
$35.37
+0.34%
(+0.12) 1D
$36.00
+1.78% (+0.63)
After hours
Closed: Oct 30, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INDV...
Open
$34.78
High
$36.49
Low
$34.62
Mkt. cap
4.17B
Avg. vol.
2.44M
Volume
4.61M
P/E ratio
12.73
52-wk high
$42.81
52-wk low
$27.68
EPS
$2.78
Beta
1.10
Shares outstanding
118.03M
No. of employees
833
Open
$34.78
High
$36.49
Low
$34.62
Mkt. cap
4.17B
Avg. vol.
2.44M
Volume
4.61M
P/E ratio
12.73
52-wk high
$42.81
52-wk low
$27.68
EPS
$2.78
Beta
1.10
Shares outstanding
118.03M
No. of employees
833
News stories
From web sources and news partners
Profile
Indivior is an American pharmaceuticals company. Established as a division of Reckitt Benckiser in 1994 and demerged from that company in December 2014, it is focussed on substitution products for opioid addiction. It is listed on the London Stock Exchange and on the NASDAQ Global Select Market. Wikipedia
About Indivior Pharmaceuticals Inc
CEOMark Crossley
Employees833
FoundedSep 26, 2014
Headquarters-
SectorPharmaceutical industry
Websiteindivior.com
Analyst ratings
Based on 3 analysts giving stock ratings to INDV in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for INDV in the last 3 months.
Highest
Current $35.37
$48.00 (+35.71%)
Average
$46.50 (+31.47%)
Lowest
$45.00 (+27.23%)
Analyst
Recommendation
Action
Price target
Projected
Date
Glen Santangelo
Barclays
Buy
Maintained
$45.00
+27.2%
10/28/2026
Chase Knickerbocker
Craig-Hallum
Buy
Maintained
-
-
09/17/2026
Brandon Folkes
H.C. Wainwright
Buy
Reiterated
$48.00
+35.7%
08/04/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$59.00
+66.8%
05/22/2026
Carl Byrnes
Northland Securities
Buy
Maintained
$50.00
+41.4%
02/27/2026
Last report
Oct 29, 2026
Fiscal period
Q3 2026
$1.32 / $1.13
+17.23%beat
Revenue / Est. (USD)
356.00M / 329.35M
+8.09%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
314.00M
358.00M
317.00M
343.00M
Cost of goods sold
46.00M
56.00M
40.00M
48.00M
Cost of revenue
46.00M
56.00M
40.00M
48.00M
Research and development expenses
20.00M
17.00M
9.00M
12.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
133.00M
155.00M
122.00M
122.00M
Operating expense
152.00M
169.00M
131.00M
134.00M
Total operating expenses
198.00M
225.00M
171.00M
182.00M
Operating income
116.00M
133.00M
146.00M
161.00M
Other non operating income
-1.00M
-
-
-
EBT including unusual items
37.00M
81.00M
115.00M
160.00M
EBT excluding unusual items
109.00M
133.00M
142.00M
162.00M
Income tax expense
-5.00M
-21.00M
26.00M
38.00M
Effective tax rate
-13.51%
-25.93%
22.61%
23.75%
Other operating expenses
-1.00M
-3.00M
-
-
Net income
42.00M
102.00M
89.00M
122.00M
Net profit margin
13.38%
28.49%
28.08%
35.57%
Earnings per share
0.72
0.82
0.96
1.15
Interest and investment income
6.00M
6.00M
3.00M
3.00M
Interest expense
-12.00M
-6.00M
-7.00M
-2.00M
Net interest expenses
-6.00M
-
-4.00M
1.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
119.00M
135.00M
148.00M
163.00M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps